

# BiOrigin ApS

c/o Cobis, Ole Maaløes Vej 3, 2200 Copenhagen N


CVR no. 38 73 41 64

## Annual report 2017

(As of the establishment of the Company 22 June - 31 December 2017)

Approved at the Company's annual general meeting on 11 May 2018

Chairman:

A handwritten signature in black ink, consisting of a series of loops and a long horizontal stroke, positioned over a dotted line.



## Contents

Statement by the Board of Directors and the Executive Board	2
Independent auditor's report	3
Management's review	5
Financial statements for the period 22 June - 31 December 2017	7
Income statement	7
Balance sheet	8
Statement of changes in equity	10
Notes to the financial statements	11



### Statement by the Board of Directors and the Executive Board

Today, the Board of Directors and the Executive Board have discussed and approved the annual report of BiOrigin ApS for the financial year as of the establishment of the Company 22 June - 31 December 2017.

The annual report is prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2017 and of the results of the Company's operations for the financial year as of the establishment of the Company 22 June - 31 December 2017.

Further, in our opinion, the Management's review gives a fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the annual general meeting.

Copenhagen, 11 May 2018  
Executive Board:



Jakob Dynnes Hansen  
CEO

Board of Directors:



Stephan Christgau  
Chairman



Emmanuelle Coutanceau

## Independent auditor's report

To the shareholders of BiOrigin ApS

### Opinion

We have audited the financial statements of BiOrigin ApS for the financial year as of the establishment of the Company 22 June - 31 December 2017, which comprise income statement, balance sheet, statement of changes in equity and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2017 and of the results of the Company's operations for the financial year as of the establishment of the company 22 June - 31 December 2017 in accordance with the Danish Financial Statements Act.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.

### Management's responsibilities for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

### Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.

## Independent auditor's report

- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- ▶ Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

## Statement on the Management's review

Management is responsible for the Management's review.


Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.


Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 11 May 2018  
ERNST & YOUNG  
Godkendt Revisionspartnerselskab  
CVR no. 30 70 02 28



Christian Schwenn Johansen  
State Authorised Public Accountant  
MNE no.: mne33234



Rasmus Bloch Jespersen  
State Authorised Public Accountant  
MNE no.: mne35503



## Management's review

### Company details

Name	BiOrigin ApS
Address, Postal code, City	c/o Cobis, Ole Maaløes Vej 3, 2200 Copenhagen N
CVR no.	38 73 41 64
Established	22 June 2017
Registered office	Copenhagen
Financial year	22 June - 31 December 2017
Board of Directors	Stephan Christgau, Chairman Emmanuelle Coutanceau
Executive Board	Jakob Dynnes Hansen, CEO
Auditors	Ernst & Young Godkendt Revisionspartnerselskab Osvold Helmuhs Vej 4, P.O. Box 250, 2000 Frederiksberg, Denmark

## **Management's review**

### **Business review**

BiOrigin ApS' primary activity consists of rendering strategic and operational support to the establishment and management of early-stage life sciences companies, primarily within the Novo Seeds portfolio, to help them steer through the critical start-up and subsequent growth phase.

### **Financial review**

In 2017, the Company's revenue amounted to DKK 225,706. The income statement for 2017 shows a loss of DKK 300,300, and the balance sheet at 31 December 2017 shows equity of DKK 2,699,700.

### **Events after the balance sheet date**

No events materially affecting the Company's financial position have occurred subsequent to the financial year-end.

## Financial statements for the period 22 June - 31 December 2017

### Income statement

Note	DKK	2017 6 months
	Revenue	225,706
	External expenses	-33,254
	<b>Gross margin</b>	<b>192,452</b>
2	Staff costs	-569,450
	<b>Profit/loss before net financials</b>	<b>-376,998</b>
	Other financial expenses	-8,002
	<b>Profit/loss before tax</b>	<b>-385,000</b>
	Tax for the year	84,700
	<b>Profit/loss for the year</b>	<b>-300,300</b>
<b>Recommended appropriation of profit/loss</b>		
	Retained earnings/accumulated loss	-300,300
		<b>-300,300</b>



## Financial statements for the period 22 June - 31 December 2017

### Balance sheet

Note	DKK	2017
<b>ASSETS</b>		
<b>Non-fixed assets</b>		
<b>Receivables</b>		
Trade receivables		46,925
Corporation tax receivable		84,700
		<u>131,625</u>
<b>Cash</b>		<u>2,741,206</u>
<b>Total non-fixed assets</b>		<u>2,872,831</u>
<b>TOTAL ASSETS</b>		<u><u>2,872,831</u></u>

## Financial statements for the period 22 June - 31 December 2017

### Balance sheet

Note	DKK	2017
	<b>EQUITY AND LIABILITIES</b>	
	<b>Equity</b>	
3	Share capital	500,000
	Retained earnings	2,199,700
	<b>Total equity</b>	<b>2,699,700</b>
	<b>Liabilities other than provisions</b>	
	<b>Current liabilities other than provisions</b>	
	Trade payables	14,048
	Other payables	159,083
		173,131
	<b>Total liabilities other than provisions</b>	<b>173,131</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2,872,831</b>
1	Accounting policies	
4	Contractual obligations and contingencies, etc.	
5	Related parties	

## Financial statements for the period 22 June - 31 December 2017

### Statement of changes in equity

DKK	Share capital	Retained earnings	Total
Cash payments concerning formation of enterprise	500,000	2,500,000	3,000,000
Transfer through appropriation of loss	0	-300,300	-300,300
<b>Equity at 31 December 2017</b>	<b>500,000</b>	<b>2,199,700</b>	<b>2,699,700</b>

## Financial statements for the period 22 June - 31 December 2017

### Notes to the financial statements

#### 1 Accounting policies

The annual report of BiOrigin ApS for 2017 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

These financial statements do not disclose comparative figures as 2017 is the first financial year of the Company.

#### Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rate at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rate at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the most recent financial statements is recognised in the income statement as financial income or financial expenses.

#### Leases

Leases that do not transfer substantially all the risks and rewards incident to the ownership to the Company are classified as operating leases. Payments relating to operating leases and any other rent agreements are recognised in the income statement over the term of the lease. The Company's aggregate liabilities relating to operating leases and other rent agreements are disclosed under "Contingent liabilities".

### Income statement

#### Revenue

Income from the rendering of services is recognised as revenue as the services are rendered. Accordingly, revenue corresponds to the market value of the services rendered during the year (percentage-of-completion method).

Revenue is measured at the fair value of the agreed consideration excluding VAT and taxes charged on behalf of third parties. All discounts and rebates granted are recognised in revenue.

#### Staff costs

Staff costs include wages and salaries, including compensated absence and pension to the Company's employees, as well as other social security contributions, etc. The item is net of refunds from public authorities.

#### Financial expenses

Financial expenses are recognised in the income statements at the amounts that concern the financial year. Net financials include interest expenses as well as allowances and surcharges under the advance-payment-of-tax scheme, etc.

## Financial statements for the period 22 June - 31 December 2017

### Notes to the financial statements

#### 1 Accounting policies (continued)

##### Tax

Tax for the year includes current tax on the year's expected taxable income and the year's deferred tax adjustments. The portion of the tax for the year that relates to the profit/loss for the year is recognised in the income statement, whereas the portion that relates to transactions taken to equity is recognised in equity.

The entity is jointly taxed with other group entities. The total Danish income tax charge is allocated between profit/loss-making Danish entities in proportion to their taxable income (full absorption).

Jointly taxed entities entitled to a tax refund are reimbursed by the management company based on the rates applicable to interest allowances, and jointly taxed entities which have paid too little tax pay a surcharge according to the rates applicable to interest surcharges to the management company.

##### Balance sheet

##### Receivables

Receivables are measured at amortised cost.

An impairment loss is recognised if there is objective evidence that a receivable or a group of receivables is impaired. If there is objective evidence that an individual receivable has been impaired, an impairment loss is recognised on an individual basis.

Impairment losses are calculated as the difference between the carrying amount of the receivables and the present value of the expected cash flows, including the realisable value of any collateral received.

##### Cash

Cash comprises cash in banks.

##### Income taxes

Current tax payables and receivables are recognised in the balance sheet as the estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

Deferred tax is measured according to the liability method on all temporary differences between the carrying amount and the tax base of assets and liabilities. However, deferred tax is not recognised on temporary differences relating to goodwill which is not deductible for tax purposes and on office premises and other items where temporary differences, apart from business combinations, arise at the date of acquisition without affecting either profit/loss for the year or taxable income. Where alternative tax rules can be applied to determine the tax base, deferred tax is measured based on Management's intended use of the asset or settlement of the liability, respectively.

Deferred tax is measured according to the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Deferred tax assets are recognised at the expected value of their utilisation; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Changes in deferred tax due to changes in the tax rate are recognised in the income statement.

## Financial statements for the period 22 June - 31 December 2017

### Notes to the financial statements

#### 1 Accounting policies (continued)

##### Other payables

Other payables are measured at net realisable value.

	2017 6 months
DKK	
<b>2 Staff costs</b>	
Wages/salaries	562,997
Other social security costs	3,012
Other staff costs	3,441
	<b>569,450</b>
	<b>2017</b>
Average number of full-time employees	<b>1</b>

#### 3 Share capital

The Company's share capital has remained DKK 500,000 since the establishment.

#### 4 Contractual obligations and contingencies, etc.

##### Other contingent liabilities

The Company is jointly taxed with its Parent, Novo Holdings A/S, which acts as the tax administrative body in relation to the joint taxation. The Company is jointly and severally liable with other jointly taxed group entities for payment of income taxes for the income year 2017 onwards as well as withholding taxes on interest, royalties and dividends falling due for payment on or after 31 December 2017.

#### 5 Related parties

##### Information about consolidated financial statements

Parent	Domicile	Requisitioning of the parent company's consolidated financial statements
Novo Nordisk Fonden	Denmark	Tuborg Havnevej 19, 2900 Hellerup